Market Overview

Vertex and Genomics plc Establish Collaboration to Use Human Genetics and Data Science to Advance Discovery of Precision Medicines


Multi-year collaboration combines expertise in genomics, machine
learning and drug discovery to identify novel targets for innovative

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) and Genomics plc
today announced a three-year collaboration, extendable to five years, to
use human genetics and machine learning to improve discovery of targets
for precision medicines, and to advance understanding of the clinical
impact of human genetic variation and patient stratification in diseases
with significant unmet need. The goal of the collaboration is to further
advance Vertex's efforts to develop transformative precision medicines
for people with serious diseases.

This press release features multimedia. View the full release here:

Genomics has developed a unique analysis engine, which uses genetics to
understand human biology and the likely efficacy and safety of potential
novel medicines. The Genomics engine is the largest of its kind in the
world, with over 100 billion data points. It links human genetic
variation at over 14 million positions in the human genome to changes in
7,000 molecular, cellular, and physiological measurements and disease
outcomes. The company uses proprietary machine learning and statistical
algorithms to predict the impact of therapeutic interventions.

"Human biology and genetics are a foundation of drug discovery at Vertex
and the team at Genomics brings together a unique combination of
sophisticated data science and human genetics," said Dr. David
Altshuler, Executive Vice President Global Research, and Chief
Scientific Officer, Vertex. "This partnership will pioneer new uses of
genomic tools and technologies to advance Vertex's ongoing work and
investment at our Oxford Research Site and globally to bring new
medicines to the patients that need them."

"Human genetics has already been shown to have a substantial impact on
the success of novel drug targets. Our next generation of data and
algorithms promises to be transformative, not just for target discovery
but in biomarker selection and patient stratification," said Professor
Peter Donnelly FRS, Founder and Chief Executive Officer, Genomics plc.
"We are delighted to be partnering with one of the most innovative and
successful companies in the global biotech sector to help realise that
promise to benefit patients and their families."

Scientists from Vertex and Genomics will work closely together to
incorporate their deep understanding of human genetics into research and
development related to target discovery and target validation in certain
diseases. Both companies will also have the opportunity to suggest
additional diseases for the collaboration, where human genetic evidence
may be particularly powerful.

In addition to funding the resources committed by Genomics to the
collaboration, Vertex will make milestone and royalty payments to the
company for novel targets resulting from the collaboration that are
taken through clinical development. Dr. Altshuler will also join the
Genomics plc Board of Directors.

Additionally, Vertex has made a £10.5 million equity investment in
Genomics plc as part of its £25 million Series B funding round also
announced today.

About Vertex

Vertex is a global biotechnology company that invests in scientific
innovation to create transformative medicines for people with serious
and life-threatening diseases. In addition to clinical development
programs in cystic fibrosis, Vertex has more than a dozen ongoing
research programs focused on the underlying mechanisms of other serious

Founded in 1989 in Cambridge, Mass., Vertex's headquarters is now
located in Boston's Innovation District. Today, the company has research
and development sites and commercial offices in the United States,
Europe, Canada and Australia. Vertex is consistently recognized as one
of the industry's top places to work, including being named to Science
magazine's Top Employers in the life sciences ranking for eight years in
a row.

For additional information and the latest updates from the company,
please visit

About Genomics plc

Genomics plc is a leading genome analysis company formed in 2014 by four
leading scientists at the University of Oxford, including Professors
Peter Donnelly (then Director of the Wellcome Centre for Human Genetics)
and Gil McVean (Director of Oxford's Big Data Institute). Its vision is
to use genomic insights to transform the drug discovery industry by
getting better drugs developed more quickly and targeted at the right
group of patients.

Every individual carries a unique set of genetic variants. Many of these
variants change aspects of our biology. The powerful idea which
underpins the company's work is that to understand the consequences of a
proposed drug one can look at individuals who happen to carry genetic
variants which affect the same part of our biology as the drug. This
human genetics approach allows Genomics to learn about human biology,
directly, in humans, rather than having to rely on the model systems
which lead to 90% of drug targets failing when they are tested in humans.

Genomics plc has developed the largest platform of its kind in the world
linking genetic variants to changes in thousands of measurements and
disease outcomes, together with breakthrough machine learning algorithms
that use this data at scale to learn directly about human biology.

Backed by some of the leading investors in life sciences, Genomics has
an expert cross-disciplinary team of over 40 people, primarily
scientists and software engineers, with offices in Oxford and Cambridge

For additional information about Genomics plc, please visit

Special Note Regarding Forward-looking Statements

This press release contains forward-looking statements as defined in the
Private Securities Litigation Reform Act of 1995, including, without
limitation, Dr. Altshuler's statements in the second paragraph of the
press release and Mr. Donnelly's statements in the third paragraph of
the press release. While Vertex believes the forward-looking statements
contained in this press release are accurate, these forward-looking
statements represent the company's beliefs only as of the date of this
press release and there are a number of factors that could cause actual
events or results to differ materially from those indicated by such
forward-looking statements. Those risks and uncertainties include, among
other things, the risks listed under Risk Factors in Vertex's annual
report and quarterly reports filed with the Securities and Exchange
Commission and available through the company's website at
Vertex disclaims any obligation to update the information contained in
this press release as new information becomes available.


View Comments and Join the Discussion!